Is targeting of CD47-SIRP  enough for treating hematopoietic malignancy?

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy

(2011) M. P. Chao et al.   BLOOD

CD47-signal regulatory protein-  (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction

(2011) X. W. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia

(2010) Mark P. Chao et al.   CANCER RESEARCH

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Macrophages as mediators of tumor immunosurveillance

(2010) Siddhartha Jaiswal et al.   TRENDS IN IMMUNOLOGY

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL